[Survival of metastatic prostate cancer: 71 patients followed for seven to eleven years].
OBJECTIVE
To refine our prognostic evaluation and consequently our therapeutic strategy to disseminated prostate cancer.


METHODS
A cohort of 71 patients with metastatic prostate cancer, recruited between 1981 and 1985, was followed for 7 to 11 years.


RESULTS
The surveillance of this cohort revealed the following median survivals: 32 months of overall survival. 1 year of clinical remission. 15 months between onset of clinical resistance and death. However, very marked variations were observed around these median durations: 17% of patients died within one year and, in contrast, 30% survived for more than 5 years.


CONCLUSIONS
Prognostic factors emerging from this study are the degree of differentiation of the primary tumour, and especially the size of the primary tumour. In some cases, this last factor could encourage the immediate coprescription of specific treatment of the primary prostatic tumour with endocrine therapy.
D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D004351:Drug Resistance; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D012074:Remission Induction; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors